Literature DB >> 26573589

Aspirin resistance and other aspirin-related concerns.

Gaoyu Cai1, Weijun Zhou2, Ya Lu3, Peili Chen2, Zhongjiao Lu1, Yi Fu4.   

Abstract

Aspirin is a widely used medication and has become a cornerstone for treating cardiovascular disease. Aspirin can significantly reduce the incidence of cardiovascular ischemic events, recurrence and mortality, thereby improving the long-term prognosis of patients. However, there has been a staggering increase in the volume of literature addressing the issue of so-called "aspirin resistance" in recent years, and for some patients, it is difficult to avoid adverse reactions to aspirin. In this review, we present both the historical aspects of aspirin use and contemporary developments in its clinical use.

Entities:  

Keywords:  Adverse effects; Aspirin; Clinical use; Resistance phenomenon

Mesh:

Substances:

Year:  2015        PMID: 26573589     DOI: 10.1007/s10072-015-2412-x

Source DB:  PubMed          Journal:  Neurol Sci        ISSN: 1590-1874            Impact factor:   3.307


  79 in total

1.  Antiplatelet drugs: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).

Authors:  Carlo Patrono; Colin Baigent; Jack Hirsh; Gerald Roth
Journal:  Chest       Date:  2008-06       Impact factor: 9.410

2.  Aspirin: a historical and contemporary therapeutic overview.

Authors:  Valentin Fuster; Joseph M Sweeny
Journal:  Circulation       Date:  2011-02-22       Impact factor: 29.690

Review 3.  The role of aspirin in cancer prevention.

Authors:  Michael J Thun; Eric J Jacobs; Carlo Patrono
Journal:  Nat Rev Clin Oncol       Date:  2012-04-03       Impact factor: 66.675

4.  Genetic determinants of response to aspirin: appraisal of 4 candidate genes.

Authors:  Marie Lordkipanidzé; Jean G Diodati; Donald A Palisaitis; Erick Schampaert; Jacques Turgeon; Chantal Pharand
Journal:  Thromb Res       Date:  2011-03-22       Impact factor: 3.944

Review 5.  Adverse effects of non-steroidal anti-inflammatory drugs (NSAIDs, aspirin and coxibs) on upper gastrointestinal tract.

Authors:  Carlos Sostres; Carla J Gargallo; Maria T Arroyo; Angel Lanas
Journal:  Best Pract Res Clin Gastroenterol       Date:  2010-04       Impact factor: 3.043

6.  Prevalence and incidence of gastroduodenal ulcers during treatment with vascular protective doses of aspirin.

Authors:  N D Yeomans; A I Lanas; N J Talley; A B R Thomson; R Daneshjoo; B Eriksson; S Appelman-Eszczuk; G Långström; J Naesdal; P Serrano; M Singh; M M Skelly; C J Hawkey
Journal:  Aliment Pharmacol Ther       Date:  2005-11-01       Impact factor: 8.171

7.  Minimal withdrawal of dual antiplatelet agents under the guidance of a point-of-care platelet activity assay early after drug-eluting stent implantation for surgical removal of renal cell carcinoma.

Authors:  Seung-Jung Park; Il-Young Oh; Kyung-Hee Kim; Dong-Ho Shin; Han-Mo Yang; Hae-Young Lee; Bon-Kwon Koo
Journal:  Int J Cardiol       Date:  2009-05-27       Impact factor: 4.164

8.  A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease.

Authors:  Patricia A Gum; Kandice Kottke-Marchant; Patricia A Welsh; Jennifer White; Eric J Topol
Journal:  J Am Coll Cardiol       Date:  2003-03-19       Impact factor: 24.094

9.  Risk of Upper Gastrointestinal Bleeding in a Cohort of New Users of Low-Dose ASA for Secondary Prevention of Cardiovascular Outcomes.

Authors:  Lucía Cea Soriano; Luis A García Rodríguez
Journal:  Front Pharmacol       Date:  2010-10-14       Impact factor: 5.810

10.  Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials.

Authors:  Colin Baigent; Lisa Blackwell; Rory Collins; Jonathan Emberson; Jon Godwin; Richard Peto; Julie Buring; Charles Hennekens; Patricia Kearney; Tom Meade; Carlo Patrono; Maria Carla Roncaglioni; Alberto Zanchetti
Journal:  Lancet       Date:  2009-05-30       Impact factor: 79.321

View more
  9 in total

1.  Advances in clinical neurology through the journal "Neurological Sciences" (2015-2016).

Authors:  Ilaria Di Donato; Antonio Federico
Journal:  Neurol Sci       Date:  2017-01       Impact factor: 3.307

2.  COX-1, COX-2 and CYP2C19 variations may be related to cardiovascular events due to acetylsalicylic acid resistance.

Authors:  Deniz Kirac; Aysun Erdem Yaman; Tansu Doran; Mujgan Mihmanli; Elif Cigdem Keles
Journal:  Mol Biol Rep       Date:  2022-01-09       Impact factor: 2.316

3.  Effect of prediabetes on asprin or clopidogrel resistance in patients with recent ischemic stroke/TIA.

Authors:  Weili Jia; Qian Jia; Yumei Zhang; Xingquan Zhao; Yongjun Wang
Journal:  Neurol Sci       Date:  2020-11-11       Impact factor: 3.307

4.  P2Y12 inhibitors in neuroendovascular surgery: An opportunity for precision medicine.

Authors:  Axel Rosengart; Malie K Collins; Philipp Hendrix; Ryley Uber; Melissa Sartori; Abhi Jain; Jennifer Mao; Oded Goren; Clemens M Schirmer; Christoph J Griessenauer
Journal:  Interv Neuroradiol       Date:  2021-02-04       Impact factor: 1.764

5.  Natural and Synthetic Neurotoxins in Our Environment: From Alzheimer's Disease (AD) to Autism Spectrum Disorder (ASD).

Authors:  Aileen I Pogue; Walter J Lukiw
Journal:  J Alzheimers Dis Parkinsonism       Date:  2016-07-26

Review 6.  Fruitflow®: the first European Food Safety Authority-approved natural cardio-protective functional ingredient.

Authors:  Niamh O'Kennedy; Daniel Raederstorff; Asim K Duttaroy
Journal:  Eur J Nutr       Date:  2016-07-07       Impact factor: 5.614

7.  Association between Multiplate-measured aspirin resistance and vitamin D deficiency in stable coronary artery disease.

Authors:  Semih Surmen; Pelin Karaca Ozer; Samim Emet; Elif Ayduk Govdeli; Ali Elitok
Journal:  Arch Med Sci Atheroscler Dis       Date:  2021-12-29

Review 8.  Diosgenin and Its Analogs: Potential Protective Agents Against Atherosclerosis.

Authors:  Dan Wang; Xiaolong Wang
Journal:  Drug Des Devel Ther       Date:  2022-07-17       Impact factor: 4.319

9.  Assessment of Risk Factors for Drug Resistance of Dual Anti Platelet Therapy After PCI.

Authors:  Lijie Zhang; Ying Lv; Jianyu Dong; Nana Wang; Zhan Zhan; Yuan Zhao; Shanshan Jiang
Journal:  Clin Appl Thromb Hemost       Date:  2022 Jan-Dec       Impact factor: 2.389

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.